MOREPEN Laboratories Ltd. (NSE: MOREPENLAB) – SWOT Analysis

Strengths (S) Diversified Pharma Business Operates across APIs, formulations, OTC healthcare products, and home diagnostic devices, reducing dependence on a single segment. Strong Presence in APIs Weaknesses (W) Pressure on Profitability Recent quarters have shown margin compression and profit volatility. Declining Quarterly Profit Trends Net profit has witnessed fluctuations, creating uncertainty regarding earnings consistency. Institutional Selling Opportunities (O) Growing Indian Healthcare Market Rising healthcare spending and increased awareness support long-term growth for pharmaceutical and diagnostic businesses. Threats (T) Intense Competition Faces competition from large domestic and multinational pharmaceutical companies. Regulatory Risks Changes in drug pricing regulations, quality compliance requirements, or export regulations may Bullish Factors Diversified pharma and healthcare portfolio. Strong API business. Established consumer healthcare brands. Growth opportunities in diagnostics and exports. Relatively healthy balance sheet. Key Risks Earnings volatility. Margin compression. Institutional selling pressure. Competitive pharmaceutical landscape. Overall Assessment MOREPEN is a small-cap pharmaceutical company with diversified operations and long-term growth potential in APIs, formulations, and home healthcare products. Investors should monitor margin trends, export growth, and profitability improvements before taking major investment decisions. Disclaimer: This SWOT analysis is for educational and informational purposes only and should not be construed as investment advice or a recommendation to buy/sell securities. Investments in the securities market are subject to market risks. Please read all related documents carefully before investing. SEBI Registration No.: INH000013174.